Show simple item record

dc.contributor.authorAldámiz-Echevarría, Teresa
dc.contributor.authorGonzález-García, Juan
dc.contributor.authorVon Wichmann, Miguel A.
dc.contributor.authorCrespo, Manel
dc.contributor.authorLópez-Aldeguer, José
dc.contributor.authorQuereda, Carmen
dc.contributor.authorTéllez, María J.
dc.contributor.authorGalindo, María J.
dc.contributor.authorSanz, José
dc.contributor.authorSantos, Ignacio
dc.contributor.authorGuardiola Tey, Josep Maria
dc.contributor.authorBellón, José M.
dc.contributor.authorMontes, Marisa
dc.contributor.authorBerenguer, Juan
dc.contributor.authorGESIDA HIV-HCV Cohort Study Group
dc.date.accessioned2021-06-17T17:16:54Z
dc.date.available2021-06-17T17:16:54Z
dc.date.issued2015
dc.identifier.citationAldámiz-Echevarría, Teresa; González-García, Juan; Von Wichmann, Miguel A. [et al.]. Association of baseline CD4+ cell count and HIV-RNA on sustained virologic response to interferon-ribavirin in HIV/HCV coinfected patients. Annals of Hepatology, 2015, 14(4), p. 464-469. Disponible en: <https://www.sciencedirect.com/science/article/pii/S1665268119311676?via%3Dihub>. Fecha de acceso: 17 jun. 2021. DOI: 10.1016/S1665-2681(19)31167-6ca
dc.identifier.issn1665-2681ca
dc.identifier.urihttp://hdl.handle.net/20.500.12328/2638
dc.description.abstractBackground and rationale for the study. We assessed the association of CD4+ T-cell counts and HIV-RNA onsustained viral response (SVR) after therapy with pegylated interferon and ribavirin (PR) in HIV/HCV coin-fected patients. We examined two large cohorts of coinfected patients treated with PR in Spain between2000 and 2008. SVR was defined as undetectable HCV-RNA at 24 weeks after the end of PR. Results.Westudied 1682 patients, of whom 38% achieved SVR. Baseline factors independently associated with reducedodds of SVR included genotype 1 or 4, HCV-RNA > 500,000 IU/mL, advanced liver fibrosis, CDC clinical cate-gory C, and detectable HIV-RNA. By multivariate logistic regression analysis, we found that, in comparisonwith patients with combination antiretroviral therapy (cART) and undetectable HIV-RNA, the odds ratio[95% confidence interval (CI)] of SVR was 0.56 (0.41-0.78) for cART and detectable HIV-RNA, 0.86 (0.56-2.57)for no-cART and detectable HIV-RNA, and 1.38 (0.74-2.57) for no-cART and undetectable HIV-RNA. Conclu-sions.Detectable HIV-RNA, but not CD4+ T-cell count, was associated with reduced odds of SVR. However,this finding was only confirmed for cART and detectable HIV-RNA, raising the question as whether this rep-resents a true association of HIV-RNA on response to PR or a spurious association due to poor adherenceto treatment.en
dc.format.extent6ca
dc.language.isoengca
dc.publisherElsevierca
dc.relation.ispartofAnnals of Hepatologyca
dc.relation.ispartofseries14;4
dc.rightsUnder a Creative Commons licenseen
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subject.otherHepatitis Cca
dc.subject.otherVirus de la immunodeficiència humanaca
dc.subject.otherInterferó pegilatca
dc.subject.otherResposta viral sostingudaca
dc.subject.otherHepatitis C crònicaes
dc.subject.otherHepatitis Ces
dc.subject.otherVirus de la inmunodeficiencia humanaes
dc.subject.otherInterferón pegiladoes
dc.subject.otherRespuesta viral sostenidaes
dc.subject.otherHepatitis C crónicaes
dc.subject.otherHepatitis Cen
dc.subject.otherHuman immunodeficiency virusen
dc.subject.otherPegilat interfereden
dc.subject.otherSustained viral responseen
dc.subject.otherChronic hepatitis Cen
dc.titleAssociation of baseline CD4+ cell count and HIV-RNA on sustained virologic response to interferon-ribavirin in HIV/HCV coinfected patientsen
dc.typeinfo:eu-repo/semantics/articleca
dc.description.versioninfo:eu-repo/semantics/publishedVersionca
dc.rights.accessLevelinfo:eu-repo/semantics/openAccess
dc.embargo.termscapca
dc.subject.udc61ca
dc.subject.udc616.9ca
dc.identifier.doihttps://dx.doi.org/10.1016/S1665-2681(19)31167-6ca


Files in this item

 

This item appears in the following Collection(s)

Show simple item record

Under a Creative Commons license
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0/
Share on TwitterShare on LinkedinShare on FacebookShare on TelegramShare on WhatsappPrint